Important clarification here, because the snarky post below was not fair to Weave Bio. Some very well established pharma companies have used Weave's AI platform to assist with regulatory submissions, successfully.

My point, made rather clumsily, is that no amount of AI gloss, no matter how smart it might be, is going to shine an ineffective drug like the one Annovis is developing for Alzheimer's. I know, because I've probably already written more about the drug than any other reporter.